Prognia
Drug Database
🇪🇺EU · EMAExpiredATC: J05AP07

Daklinza(daclatasvir dihydrochloride)

Hepatitis C, Chronic

Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG

EMA Authorisation: 22/08/2014

INN: daclatasvir

Indication

Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1). For HCV genotype specific activity, see sections 4.4 and 5.1.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Daklinza — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.